MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram

Important Resources for the MS community are found on the left side of this blog.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Friday, September 3, 2010

Most Neurologists Yet to Be Cautious, Plan To Prescribe Oral Multiple Sclerosis Drugs

Article Date: 03 Sep 2010


In a study published this week by Majestic Research, almost 60% of neurologists expressed unaided concern about the side effects/safety of oral MS therapies in development, including NVS's Gilenia and MRK/EMD Serono's oral cladribine. Despite their concerns, the vast majority of neurologists expect to prescribe these drugs if they are approved, as the new oral MS therapies are expected to be highly efficacious and more convenient for patients than available injectable therapies. Data from the study suggests that new orals will steal share primarily frommultiple sclerosis market leaders, including BIIB's Avonex and TEVA'sCopaxone. 

The study titled Event Pulse Preview: Multiple Sclerosis shows that 84% of neurologists expect to prescribe Gilenia for some MS patients if approved, but prescribing will likely be limited to second- or third-line therapy until concerns about safety and monitoring requirements are resolved. Jemma Lampkin, Director of Market Research, said, "Neurologists are clearly worried about the side effects that have come up in the clinical trials for these drugs in development, and the negative press regarding Tysabri's PML cases over the past few years also seems to be a factor. Still, almost all of the neurologists in this study expect to prescribe Gilenia, so there is optimism regarding its potential." The study suggests that Gilenia, which is expected to be approved in September 2010, could have a more significant impact than some have predicted. 




Continue reading


***********************************************************
"Providing You with 'MS Views and News'is what we do"
Keep Informed and up-to-date with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************

2 comments:

Cherie said...

Fingolimod has a higher risk of death due to reactivated herpes infections (about 1:600) than PML in Tysabri recipients (1:5000 in the first year and 1:1000 after two years). Cladribine, suppresses the immune system preventing the ability to fight infection for a period of 8-18 months with no known means to reverse this suppression.

So...these two oral medications will not be used routinely for people who do not want to use injectables but will be used, as the article says, as a second or third line of defense for those persons who have failed the injectables, Tysabri and Novantrone and are continuing to worsen.

This information is borne out in the study literature that has been submitted to the FDA and in abstracts of the oral trials submitted to the CMSC (Consortium of Multiple Sclerosis Centers) annual meeting in June of this year.

Sean said...

Were you aware that there are currently clinical trials of the GEN 2 of fingolomid that is reputed to be almost side-effect free? In addition the immune system recovery is as short as 2 DAYS (what my neuro told me).
Seems to good to be true.....